Depot leuprolide acetate 3.75 mg (DrugBank: Leuprolide, Acetate)
5 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
1 | Spinal and bulbar muscular atrophy | 0 |
2 | Amyotrophic lateral sclerosis | 0 |
3 | Spinal muscular atrophy | 0 |
51 | Scleroderma | 1 |
76 | Pituitary gonadotropin secretion hyperthyroidism | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01257802 (ClinicalTrials.gov) | May 2011 | 9/12/2010 | GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases | GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases | Lupus Erythematosus, Systemic;Systemic Vasculitis;Isolated Angiitis of Central Nervous System;Lung Disease With Systemic Sclerosis;Lung Disease Interstitial Diffuse | Drug: depot leuprolide acetate 3.75 mg;Drug: Placebo | Joseph Mccune | National Institutes of Health (NIH);Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Terminated | 18 Years | 40 Years | Female | 14 | Phase 3 | United States |